MDx/CDx Focus: Qiagen; Dako & Amgen; Ventana & Pfizer; Foundation Medicine & Sanofi; and More
January 11, 2012
MDx/CDx Focus: Qiagen; Dako & Amgen; Ventana & Pfizer; Foundation Medicine & Sanofi; and More
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- PGx Drugs Xalkori, Zelboraf Show Strong Growth in First Quarter of 2013
May 1, 2013 / Pharmacogenomics Reporter - Patient Enrichment to Limit PGx Testing for NSCLC Could Lower Costs, but Miss Responders
March 21, 2012 / Pharmacogenomics Reporter - Personalized Medicine in 2012: Industry Takes a Wait-and-See Approach Due to Market Unknowns
January 9, 2013 / Pharmacogenomics Reporter - Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: Studies Reported At ESMO on Roche's Herceptin, T-DM1, Pfizer's Xalkori
October 3, 2012 / Pharmacogenomics Reporter